In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

How to manage the NOACs in clinical practice, a case-based approach

EHRA webinar

Add to calendar25/09/20130:00 25/09/20130:00 Europe/Paris How to manage the NOACs in clinical practice, a case-based approach European Heart Rhythm Association contact@escardio.org DD/MM/YYYY
Stroke
Cardiovascular Pharmacology and Pharmacotherapy
Atrial Fibrillation
Arrhythmias

 

Hein Heidbuchel, Marco Alings and Paulus Kirchhof discuss the management of NOACs in daily practice.

Apart from the study results, are all NOACs equal for everyday use? What do we have to consider when deciding on the dose? How long to stop in anticipation of a procedure, and what to do in case of bleeding? Prescription-and-go, or do we need to follow-up on those NOAC patients, and how? And what to do if there is an indication for both an antiplatelet drug and anticoagulation? You certainly have pondered over these questions. Our faculty will try to provide you with answers.

Novel Oral Anticoagulants for Atrial Fibrillation
NOAC for AF Practical Guide
 

European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation 

The EHRA Webinars are designed to help you improve your daily practice!
The format includes a case based presentation, online assesssment and live discussions with the 3 key opinion leaders who will give you some useful tips for your daily clinical practice.

 

 

 

This programme is supported by Bayer in the form of unrestricted educational grants.
The scientific programme has not been influenced in any way by its sponsor.